Video Experimental Relacionado
Updated: Aug 9, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Respuesta engañosa de las úlceras gástricas malignas a la cimetidina
La cimetidina curó úlceras gástricas de apariencia benigna, pero los síntomas regresaron después de la interrupción del tratamiento. Dos pacientes tenían cáncer intramucoso no detectado, lo que pone de relieve los riesgos de un diagnóstico tardío de úlceras gástricas malignas.
Área de la Ciencia:
- Gastroenterología y Gastroenterología.
- Oncología Oncología.
- Farmacología Farmacología.
Sus antecedentes:
- Úlceras gástricas (G.U.) también conocidas como úlceras gástricas. Son afecciones gastrointestinales comunes que a menudo se tratan con medicamentos.
- La cimetidina es un antagonista de los receptores de histamina H2 utilizado para reducir la producción de ácido estomacal.
- El diagnóstico preciso de la etiología de la úlcera gástrica (benigna vs. maligna) es crucial para el tratamiento adecuado.
Videos de Conceptos Relacionados
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

